An Open-label Dose Escalation and Expansion Phase 1/2 Study to Evaluate the Safety Tolerability Pharmacokinetics Pharmacodynamics and Preliminary Antitumor Activit of TAK-500 a Novel Stimulator of Interferon Genes Agonist as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Select Locally Advanced or Metastatic Solid Tumors

Brief description of study

This study is about a new medicine called TAK-500. We want to see if it is safe and if it works well by itself or with another medicine called pembrolizumab. The study has two parts. First, we will try different amounts of TAK-500 to see which one has the fewest side effects and still works well. Then, we will give this amount to people who have certain types of cancer. People with serious cancers, like those in the throat, stomach, pancreas, liver, lungs, head, neck, and kidney, as well as a type of breast cancer and a cancer called mesothelioma, will join the study. We want to see if the medicine doesn't make people feel too sick, how it works in the body, and if it helps fight the cancer.


Clinical Study Identifier: s24-00297
ClinicalTrials.gov Identifier: NCT05070247
Principal Investigator: Minas Platon Economides.
Other Investigators: Scot Niglio, Victor Ricardo Adorno Febles, Hank Ng, David R. Wise.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.